Literature DB >> 18972123

Induction chemotherapy with paclitaxel and cisplatin followed by radiotherapy for larynx organ preservation in advanced laryngeal and hypopharyngeal cancer offers moderate late toxicity outcome (DeLOS-I-trial).

Andreas Dietz1, Volker Rudat, Jens Dreyhaupt, Maria Pritsch, Florian Hoppe, Rudolph Hagen, Leo Pfreundner, Ursula Schröder, Hans Eckel, Markus Hess, Michael Schröder, Petra Schneider, Bünzel Jens, Hans P Zenner, Jochen A Werner, Rita Engenhardt-Cabillic, Bernhard Vanselow, Peter Plinkert, Marcus Niewald, Thomas Kuhnt, Wilfried Budach, Michael Flentje.   

Abstract

A prospective multicenter phase-II trial (12 centers) was performed by the German larynx organ preservation group (DeLOS) to evaluate the effect of induction chemotherapy (ICHT) with paclitaxel/cisplatin (TP), followed by accelerated-hyperfractionated (concomitant boost) radiotherapy (RT) in responders. The trial was focused on larynx preservation, tumor control, survival, salvage surgery and late toxicity in patients with advanced larynx/hypopharynx carcinoma eligible for total laryngectomy (LE). Seventy-one patients (40 larynx, 87.5% St. III, IV; 31 hypopharynx, 93.4% St. III, IV) were enrolled into the study and treated with ICHT (200 mg/m(2) paclitaxel, 100 mg/m(2) cisplatin; day 1, 22) according to the DeLOS protocol. Patients with complete or partial tumor response proceeded to RT (69.9 Gy in 5.5 weeks). Non-responders received a LE followed by postoperative RT (56-70 Gy in 5.5-7 weeks). The response rate to ICHT for larynx cancer was 69.6% (7.1% complete, 62.5% partial response) and for hypopharyngeal cancer was 84.3% (6.9% complete, 77.4% partial response). Overall survival after 36 months was 60.3% (95% CI, 48.4-72.2%), after 42 months was 56.5% (95% CI, 44.2-68.8%). Laryngectomy-free survival was as follows: after 36 months, 43.0% (95% CI, 30.9-55.0%); after 42 months, 41.3% (95% CI, 29.3-53.3%). Both parameters did not show different outcomes after distinguishing larynx from hypopharynx. LE was indicated in 15 non-responders after ICHT. Five of the 15 non-responders refused the laryngectomy. Two of the five received RT instead and had no evidence of disease 42 months after RT. Late toxicity (dysphagia III, IV LENT SOMA score in laryngectomy-free survivors: after 6 months, 1.8%; 12 months, 11.4%; 18 months, 14.5%; 24 months, 8.1%; 36 months, 16%) and salvage surgery (4 pharyngocutaneous fistulas in 27 operations) were tolerable. In a large portion of patients eligible for LE, the larynx could be preserved with satisfying functional outcome. Good responders after ICHT had also a good general outcome with relatively rare severe late toxicities. Due to a slight increase of relevant late dysphagia, functional outcome regarding swallowing and tracheotomy free breathing should be more focused in future larynx organ preservation trials.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18972123     DOI: 10.1007/s00405-008-0846-y

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  24 in total

1.  Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer.

Authors:  J P Pignon; J Bourhis; C Domenge; L Designé
Journal:  Lancet       Date:  2000-03-18       Impact factor: 79.321

2.  Laryngeal cancer in the United States: changes in demographics, patterns of care, and survival.

Authors:  Henry T Hoffman; Kimberly Porter; Lucy H Karnell; Jay S Cooper; Randall S Weber; Corey J Langer; Kie-Kian Ang; Greer Gay; Andrew Stewart; Robert A Robinson
Journal:  Laryngoscope       Date:  2006-09       Impact factor: 3.325

Review 3.  Does induction chemotherapy have a role in the management of locoregionally advanced squamous cell head and neck cancer?

Authors:  David J Adelstein; Michael Leblanc
Journal:  J Clin Oncol       Date:  2006-06-10       Impact factor: 44.544

4.  The laryngologist in organ preservation for laryngeal cancer.

Authors:  Daniel F Brasnu; Dana M Hartl
Journal:  Laryngoscope       Date:  2008-04       Impact factor: 3.325

Review 5.  Functional outcomes following treatment for advanced laryngeal cancer. Part I--Voice preservation in advanced laryngeal cancer. Part II--Laryngectomy rehabilitation: the state of the art in the VA System. Research Speech-Language Pathologists. Department of Veterans Affairs Laryngeal Cancer Study Group.

Authors:  R E Hillman; M J Walsh; G T Wolf; S G Fisher; W K Hong
Journal:  Ann Otol Rhinol Laryngol Suppl       Date:  1998-05

Review 6.  Prevention and treatment of dysphagia and aspiration after chemoradiation for head and neck cancer.

Authors:  David I Rosenthal; Jan S Lewin; Avraham Eisbruch
Journal:  J Clin Oncol       Date:  2006-06-10       Impact factor: 44.544

7.  Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: a new treatment paradigm.

Authors:  Susan Urba; Gregory Wolf; Avraham Eisbruch; Francis Worden; Julia Lee; Carol Bradford; Theodoros Teknos; Douglas Chepeha; Mark Prince; Norman Hogikyan; Jeremy Taylor
Journal:  J Clin Oncol       Date:  2005-12-27       Impact factor: 44.544

8.  Induction chemotherapy with paclitaxel and cisplatin and CT-based 3D radiotherapy in patients with advanced laryngeal and hypopharyngeal carcinomas--a possibility for organ preservation.

Authors:  Leo Pfreundner; Florian Hoppe; Jochen Willner; Verena Preisler; Klaus Bratengeier; Rudolf Hagen; Jan Helms; Michael Flentje
Journal:  Radiother Oncol       Date:  2003-08       Impact factor: 6.280

9.  [Chronic laryngeal edema as a late reaction to radiochemotherapy].

Authors:  A Dietz; V Rudat; J Nollert; M Helbig; B Vanselow; H Weidauer
Journal:  HNO       Date:  1998-08       Impact factor: 1.284

10.  Transoral laser microsurgery for advanced laryngeal cancer.

Authors:  Michael L Hinni; John R Salassa; David G Grant; Bruce W Pearson; Richard E Hayden; Alexios Martin; Hans Christiansen; Bruce H Haughey; Brian Nussenbaum; Wolfgang Steiner
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2007-12
View more
  18 in total

1.  [Multimodal laryngeal preservation: current data-based opinion].

Authors:  A Dietz; A Boehm; G Wichmann; D Niederwieser; S Dietzsch; M Fuchs
Journal:  HNO       Date:  2012-01       Impact factor: 1.284

2.  Comparison of three different concurrent chemoradiation regimens for treatment of laryngeal cancer.

Authors:  Utku Aydil; Müge Akmansu; Özge Gumusay; Faruk Kadri Bakkal; Ömer Yazıcı; Yusuf Kızıl; Ahmet Köybaşıoğlu; Ramazan Yıldız; Süleyman Büyükberber; Erdoğan İnal
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-12-18       Impact factor: 2.503

3.  [Recent advances in the treatment of laryngeal and hypopharyngeal carcinoma].

Authors:  H E Eckel
Journal:  HNO       Date:  2012-01       Impact factor: 1.284

4.  Laryngeal sensation and pharyngeal delay time after (chemo)radiotherapy.

Authors:  Takashi Maruo; Yasushi Fujimoto; Kikuko Ozawa; Mariko Hiramatsu; Atsushi Suzuki; Naoki Nishio; Tsutomu Nakashima
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-10-23       Impact factor: 2.503

Review 5.  Effectiveness of chemotherapy and radiotherapy for laryngeal preservation in advanced laryngeal cancer: a meta-analysis and systematic review.

Authors:  Xiao-Ning Luo; Liang-Si Chen; Si-Yi Zhang; Zhong-Ming Lu; Yan Huang
Journal:  Radiol Med       Date:  2015-05-16       Impact factor: 3.469

6.  Incidence and localization of abnormal mucosa findings in patients consulting ENT outpatient clinics and data analysis of a cancer registry.

Authors:  J Löhler; A O H Gerstner; F Bootz; L E Walther
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-10-10       Impact factor: 2.503

7.  [Prevalence of abnormal mucosal findings in patients in HNO practices].

Authors:  J Löhler; A O H Gerstner; F Bootz; H Heinritz; A Fryen; G Fryen; N Holstein; A Lingg; J Kleeberg; W Langhoff; G Rösch; A Hanisch; E Schneeberg; D Heinrich; L E Walther
Journal:  HNO       Date:  2012-03       Impact factor: 1.284

8.  The role of chemotherapy in the management of patients with head and neck cancer.

Authors:  Panayiotis Panos Savvides
Journal:  Semin Plast Surg       Date:  2010-05       Impact factor: 2.314

9.  Assay-based response evaluation in head and neck oncology: requirements for better decision making.

Authors:  Andreas Dietz; Andreas Boehm; Iris-Susanne Horn; Pierre Kruber; Ingo Bechmann; Wojciech Golusinski; Dietger Niederwieser; Ralph Dollner; Torsten W Remmerbach; Christian Wittekind; Stephan Dietzsch; Guido Hildebrandt; Gunnar Wichmann
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-01-06       Impact factor: 2.503

10.  Evaluation of the revised TNM classification in advanced laryngeal cancer.

Authors:  G Psychogios; F Waldfahrer; A Bozzato; H Iro
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-01       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.